Sanofi loses bid to revive Lantus Solostar insulin-pen patents

In a win for Sanofi-competitor Viatris, Sanofi's attempt to keep its patent for the blockbuster insulin injection pen, Lantus SoloStar, has been rejected by the US Court of Appeals.
Photo: CHARLES PLATIAU/Reuters / X00217
Photo: CHARLES PLATIAU/Reuters / X00217
By Susan Decker, bloomberg

Sanofi lost its appeals court bid to revive patents on its blockbuster Lantus SoloStar insulin injection pen in a victory for drugmaker Viatris Inc. 

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading